To Demonstrate the Relative Bioavailability of Atenolol Tablets
NCT ID: NCT00913965
Last Updated: 2017-03-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
24 participants
INTERVENTIONAL
1989-07-31
1989-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Relative Bioavailability Study of Nadolol (1 x 80 mg) Tablets Under Fasting Conditions
NCT00960245
Effect of SLCO2B1 Genotype and Apple Juice on Pharmacokinetics of Atenolol After Oral Administration in Healthy Male Korean
NCT01445964
Effect of Carvedilol Controlled-Release (CR) and Atenolol on Central Blood Pressure
NCT00669279
Perioperative Effect of Atenolol on Cytokine Profiles
NCT00202358
Genetic Determinants of Response to Beta Blockade
NCT00837902
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Atenolol Tablets 100 mg (Cord Laboratories)
Atenolol Tablets 100 mg (Cord Laboratories)
2
Atenolol Tablets 100 mg (Stuart Pharmaceutical)
Atenolol Tablets 100 mg (Stuart Pharmaceutical)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atenolol Tablets 100 mg (Cord Laboratories)
Atenolol Tablets 100 mg (Stuart Pharmaceutical)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Treatment for drug or alcohol dependence.
19 Years
50 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sandoz
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sandoz Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rudolph C. Cane, Jr., M.D.
Role: PRINCIPAL_INVESTIGATOR
PharmaKinetics Laboratories Inc.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
9103B
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.